1076P - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma

Abstract

Listen

Translate article

BackgroundNo previous study has evaluated the prognostic value of coagulation factors in patients with early-stage natural killer/T-cell lymphoma (NKTCL). The aim of this study was to investigate the relationships between coagulation function and clinical response and prognosis in patients with early-stage NKTCL. MethodsThe data of patients with stage I/II NKTCL who were treated in Cancer Hospital, Chinese Academy of Medical Sciences from January 2008 to January 2019 were collected and studied retrospectively. Data included patients’ clinical characteristics and related indexes of coagulation function before treatment (preoperative activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin time activity (PTA), fibrinogen (FIB), international normalized ratio (INR), D-dimer, and platelet count (PLT)). The cut-off value was set as the median of pretreatment coagulation factors. ResultsA total of 159 patients with stage I/II NKTCL were included in this study. Abnormal coagulation function was found in nearly half of (49.69%) patients, and increased D-dimer(16.28%) and FIB(11.25%) were the most common abnormalities. Univariate analysis showed that increased D-dimer level (P<0.001) and increased FIB level (P=0.021) reduced complete remission (CR) rate. In addition to other prognostic factors including Eastern cooperative oncology group (ECOG) score≥2, B symptom, increased lactate dehydrogenase (LDH) level, increased D-dimer level was also demonstrated to be associated with the unfavorable progression-free survival (PFS) (P=0.003) and overall survival (OS) (P=0.002). Multivariate analysis indicated that increased D-dimer level was an independent factor for poor clinical response (P=0.008), PFS (P=0.021) and OS (P=0.007). ConclusionsOur study suggested that elevated pretreatment coagulation factors especially D-dimer and plasma FIB were unfavorable predictors for clinical response, OS and PFS in early-stage NKTCL. Legal entity responsible for the studyDong Mei. FundingThe Cancer Foundation of China, Beijing Hope Marathon Project Fund. DisclosureAll authors have declared no conflicts of interest.